Hepatitis Monthly

Published by: Kowsar

Performance of Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) for Hepatocellular Carcinoma Screening in Chinese Population

Rentao Yu 1 , Shitao Ding 1 , 2 , Wenting Tan 1 , 2 , Shun Tan 1 , 2 , Zhaoxia Tan 1 , 2 , Shiqing Xiang 3 , Yi Zhou 1 , 2 , Qing Mao 1 , 2 and Guohong Deng 1 , 2 , 4 , *
Authors Information
1 Department of Infectious Diseases, Southwest Hospital, Third Military Medical University, Chongqing, China
2 Chongqing Key Laboratory of Infectious Diseases, Southwest Hospital, Third Military Medical University, Chongqing, China
3 Department of Laboratory Diagnosis, Southwest Hospital, Third Military Medical University, Chongqing, China
4 Institute of Immunology, Third Military Medical University, Chongqing, China
Article information
  • Hepatitis Monthly: July 01, 2015, 15 (7); e28806
  • Published Online: July 22, 2015
  • Article Type: Research Article
  • Received: March 19, 2015
  • Revised: June 1, 2015
  • Accepted: June 10, 2015
  • DOI: 10.5812/hepatmon.28806v2

To Cite: Yu R, Ding S, Tan W, Tan S, Tan Z, et al. Performance of Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) for Hepatocellular Carcinoma Screening in Chinese Population, Hepat Mon. 2015 ; 15(7):e28806. doi: 10.5812/hepatmon.28806v2.

Copyright © 2015, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001; 94(2): 153-6[PubMed]
  • 2. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004; 127(5 Suppl 1)[PubMed]
  • 3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2): 74-108[PubMed]
  • 4. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012; 142(6): 1264-1273 e1[DOI][PubMed]
  • 5. Bruix J, Sherman M, American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53(3): 1020-2[DOI][PubMed]
  • 6. Llovet JM, Bruix J. Early diagnosis and treatment of hepatocellular carcinoma. Baillieres Best Pract Res Clin Gastroenterol. 2000; 14(6): 991-1008[DOI][PubMed]
  • 7. Ioannou GN, Perkins JD, Carithers RJ. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology. 2008; 134(5): 1342-51[DOI][PubMed]
  • 8. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010; 4(2): 439-74[DOI][PubMed]
  • 9. Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 2008; 68(5): 1451-61[DOI][PubMed]
  • 10. Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol. 2005; 43(3): 434-41[PubMed]
  • 11. Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med. 1984; 310(22): 1427-31[DOI][PubMed]
  • 12. Sakizono K, Oita T, Kuroda M, Kasakura S. [Development of highly sensitive assay for detection of low serum level of PIVKA-II and its clinical usefulness]. Rinsho Byori. 1996; 44(9): 871-6[PubMed]
  • 13. Nakao A, Virji A, Iwaki Y, Carr B, Iwatsuki S, Starzl E. Abnormal prothrombin (DES-gamma-carboxy prothrombin) in hepatocellular carcinoma. Hepatogastroenterology. 1991; 38(5): 450-3[PubMed]
  • 14. Tanaka T, Taniguchi T, Sannomiya K, Takenaka H, Tomonari T, Okamoto K, et al. Novel des-gamma-carboxy prothrombin in serum for the diagnosis of hepatocellular carcinoma. J Gastroenterol Hepatol. 2013; 28(8): 1348-55[DOI][PubMed]
  • 15. Song P, Gao J, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, et al. Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china. Liver Cancer. 2013; 2(1): 31-9[DOI][PubMed]
  • 16. Asia-Pacific Working Party on Prevention of Hepatocellular C. Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements. J Gastroenterol Hepatol. 2010; 25(4): 657-63[DOI][PubMed]
  • 17. Grazi GL, Mazziotti A, Legnani C, Jovine E, Miniero R, Gallucci A, et al. The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin. Liver Transpl Surg. 1995; 1(4): 249-55[PubMed]
  • 18. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009; 137(1): 110-8[DOI][PubMed]
  • 19. Volk ML, Hernandez JC, Su GL, Lok AS, Marrero JA. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark. 2007; 3(2): 79-87[PubMed]
  • 20. Li C, Zhang Z, Zhang P, Liu J. Diagnostic accuracy of des-gamma-carboxy prothrombin versus alpha-fetoprotein for hepatocellular carcinoma: A systematic review. Hepatol Res. 2014; 44(10)-25[DOI][PubMed]
  • 21. Sharma B, Srinivasan R, Chawla YK, Kapil S, Saini N, Singla B, et al. Clinical utility of prothrombin induced by vitamin K absence in the detection of hepatocellular carcinoma in Indian population. Hepatol Int. 2010; 4(3): 569-76[DOI][PubMed]
  • 22. Tateishi R, Yoshida H, Matsuyama Y, Mine N, Kondo Y, Omata M. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatol Int. 2008; 2(1): 17-30[DOI][PubMed]
  • 23. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010; 138(2): 493-502[DOI][PubMed]
  • 24. Ertle JM, Heider D, Wichert M, Keller B, Kueper R, Hilgard P, et al. A combination of alpha-fetoprotein and des-gamma-carboxy prothrombin is superior in detection of hepatocellular carcinoma. Digestion. 2013; 87(2): 121-31[DOI][PubMed]
  • 25. European Association For The Study Of The L, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012; 56(4): 908-43[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments